Abstract:Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): West Midlands Academic Health Science Network. Background After an acute coronary syndrome (ACS), there is a persistent ~10% risk of recurrent ACS or death in the following year and a further ~10% risk between years 1-4. Several more recent guideline-recommended treatments that could reduce this risk (Knuuti et al 2019) and may be under-utilised. Some of these, such as long-term dual antithrombotic therapy, are recommended for patients with high cardiovascular risk. Others benefit patients with type 2 diabetes mellitus (SGLT2 inhibitors and GLP1 agonists), hypercholesterolaemia (ezetimibe and PCSK9 inhibitors) or heart failure (mineralocorticoid antagonists and sacubitril/valsartan in addition to ACE inhibitors and beta blockers). Methods We were recently awarded funding from the West Midlands Academic Health Science Network (UK) to introduce a new advanced secondary prevention clinic that focusses on more recent medications with recommendations from National Institute for Health and Care Excellence (NICE NG185 and relevant technology appraisals) and the ESC. In an audit we compared use of medications in the prevention clinic (n=57) with similar patients with prior ACS seen in standard cardiology clinics (n=109) between 2020-21 in our National Health Service (NHS) Trust (Fig 1.). Results Assessment of eligibility for medications was complex, but showed similar eligibility in prevention clinics and standard clinics. Patients were uniformly eligible for statins and ACE inhibitors, whereas NICE and ESC guidelines in some cases disagreed on eligibility of individual patients for dual antithrombotic therapy, beta blockers and ezetimibe. Use of treatments with definitive guideline recommendations from both NICE and ESC was determined for each patient (Fig 1). There was significantly higher adherence to these definitive recommendations in prevention vs. standard clinics (Fig 1), including SGLT2 inhibitors/GLP1 agonists (17/18 [94%] vs. 5/29 [17%]; P<0.001), PCSK9 inhibitors (3/3 [100%] vs. 0/6 [0%]; P=0.01), ezetimibe (23/25 [92%] vs. 11/48 [23%]; P<0.001], long-term dual antithrombotic therapy (22/23 [96%] vs. 3/31 [10%]; P<0.001]) and statins at a recommended dose (52/53 [98%] vs. 82/101 [81%]; P<0.001. Peer consultation identified several barriers to use of medications: complexity of treatment algorithms (which often differ between guidelines); need for personalisation (the audit identified >50 unique combinations of recommended treatments for individual patients); complex risk assessments; and time constraints in gathering data to assess eligibility the medications (often takes >5 min), exacerbated by high patient volume. Conclusions Several guideline-recommended medications with established cardiovascular benefit were under-utilised in standard clinics after ACS. Specialist preventative cardiology clinics can optimise utilisation of these medications, which has the potential to reduce the risk of further major adverse cardiovascular events. Innovative solutions are needed to scale this further.

An evaluation of the best practices and barriers for the Nagasaki acute myocardial infarction secondary prevention clinical pathway

Impact of Implementation of a Region-Wide Low-Density Lipoprotein Cholesterol Management Clinical Pathway for the Secondary Prevention of Acute Myocardial Infarction

Cost-effectiveness analysis of implementing the Nagasaki Acute Myocardial Infarction (AMI) secondary prevention clinical pathway

National survey on the secondary preventive measures for coronary artery disease among interventional cardiologists: a report from the Japanese Association of Cardiovascular Intervention and Therapeutics

The PACIFIC (Prevention of AtherothrombotiC Incidents Following Ischemic Coronary attack) Registry: Rationale and Design of a 2-Year Study in Patients Initially Hospitalised with Acute Coronary Syndrome in Japan

Online Intensive Cardiac Rehabilitation Program for Japanese Patients With Coronary Artery Disease - A Pilot Study Protocol

CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) in 2018

Efficacy of online japanese intensive cardiac rehabilitation for secondary prevention for coronary artery disease: a comprehensive program including exercise, nutrition, mindfulness, and group support

Trends in antithrombotic therapy and clinical outcomes for percutaneous coronary intervention in Japan following the 2020 JCS guideline focused update: findings from the SAKURA PCI2 Antithrombotic Registry

A Web-Based Education Program About Primary Palliative Care for Heart Failure: A Study Protocol of Wait-Listed Randomized Controlled Trial

Factors Associated With Regional Differences in Healthcare Quality for Patients With Acute Myocardial Infarction in Japan

A Critical Pathway for Management of Patients with Acute Chest Pain Who Are at Low Risk for Myocardial Ischemia: Recommendations and Potential Impact

Lipid Management and 2-Year Clinical Outcomes in Japanese Patients with Acute Coronary Syndrome: EXPLORE-J

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020

Comparison of care and outcomes for myocardial infarction by heart failure status between United Kingdom and Japan

Rationale, Design, and Baseline Characteristics of the Prospective Japan Acute Myocardial Infarction Registry (JAMIR)

Identifying and Solving Gaps in Pre- and In-Hospital Acute Myocardial Infarction Care in Asia-Pacific Countries

Improved adherence to guideline-recommended treatments in a specialist preventative pharmacology clinic compared to standard cardiology clinics after an acute coronary syndrome

A Systematic Review of Lipid Management in Secondary Prevention and Comparison of International Lipid Management Pathways

Acute coronary syndrome in the Asia-Pacific region

Survey of patients with stroke in the Kitakyushu Area, Japan: a 12-year retrospective analysis of the critical pathway